JO3357B1 - مركبات إيميدازوبيروليدينون - Google Patents

مركبات إيميدازوبيروليدينون

Info

Publication number
JO3357B1
JO3357B1 JOP/2013/0025A JOP20130025A JO3357B1 JO 3357 B1 JO3357 B1 JO 3357B1 JO P20130025 A JOP20130025 A JO P20130025A JO 3357 B1 JO3357 B1 JO 3357B1
Authority
JO
Jordan
Prior art keywords
compounds
imidazopyrrolidinone
imidazopyrrolidinone compounds
adisorder
mdm4
Prior art date
Application number
JOP/2013/0025A
Other languages
English (en)
Inventor
Mao Liang
Vaupel Andrea
Schlabach Achim
Furet Pascal
Kallen Joerg
Mah Robert
Stutz Stefan
Guagnano Vito
Holzer Philipp
Masuya Keiichi
Liao Lv
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3357(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3357B1 publication Critical patent/JO3357B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

بتعلق الاختراع بمركبات إيميدازوبيروليدينون جديدة لها الصيغة (I) كما وصف هنا ، مستحضرات صيدلانية تتضمن تلك المركبات ، استخداماته و طرق استخدام تلك المركبات لمعالجة اضطراب أو مرض و الذي ينشأ عبر فاعلية MDM2 و / أو MDM4 و اتحادات تتضمن تلك المركبات.
JOP/2013/0025A 2012-01-26 2013-01-24 مركبات إيميدازوبيروليدينون JO3357B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591001P 2012-01-26 2012-01-26
US201261669902P 2012-07-10 2012-07-10
CNPCT/CN2012/086703 2012-12-14

Publications (1)

Publication Number Publication Date
JO3357B1 true JO3357B1 (ar) 2019-03-13

Family

ID=47997596

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0025A JO3357B1 (ar) 2012-01-26 2013-01-24 مركبات إيميدازوبيروليدينون

Country Status (44)

Country Link
US (2) US8815926B2 (ar)
EP (3) EP3272754B1 (ar)
JP (3) JP5865519B2 (ar)
KR (2) KR101694383B1 (ar)
CN (1) CN104203952B (ar)
AP (1) AP2014007810A0 (ar)
AR (1) AR089807A1 (ar)
AU (1) AU2013213260B2 (ar)
BR (1) BR112014018475B1 (ar)
CA (1) CA2860951C (ar)
CL (1) CL2014001855A1 (ar)
CO (1) CO7010838A2 (ar)
CR (1) CR20140354A (ar)
CU (1) CU24336B1 (ar)
CY (1) CY1119058T1 (ar)
DK (1) DK2807164T3 (ar)
DO (1) DOP2014000170A (ar)
EA (2) EA027130B1 (ar)
EC (1) ECSP14015553A (ar)
ES (2) ES2743962T3 (ar)
GE (1) GEP20166438B (ar)
GT (1) GT201400164A (ar)
HK (2) HK1198761A1 (ar)
HR (1) HRP20171005T1 (ar)
IL (1) IL233739A (ar)
JO (1) JO3357B1 (ar)
LT (1) LT2807164T (ar)
MA (1) MA35869B1 (ar)
MX (1) MX353315B (ar)
MY (1) MY177242A (ar)
NI (1) NI201400083A (ar)
NZ (1) NZ627277A (ar)
PE (1) PE20141655A1 (ar)
PH (1) PH12014501702A1 (ar)
PL (1) PL2807164T3 (ar)
PT (1) PT2807164T (ar)
RS (1) RS56197B1 (ar)
SG (1) SG11201403935VA (ar)
SI (1) SI2807164T1 (ar)
TN (1) TN2014000319A1 (ar)
TW (2) TW201713644A (ar)
UA (1) UA115231C2 (ar)
UY (1) UY34591A (ar)
WO (1) WO2013111105A1 (ar)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP6373978B2 (ja) * 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
CA2931249A1 (en) * 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US20160331751A1 (en) * 2013-12-23 2016-11-17 Novartis Ag Pharmaceutical compositions
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
US20180243293A1 (en) * 2015-08-14 2018-08-30 Novartis Ag Pharmaceutical combinations and their use
JP2018528206A (ja) * 2015-08-28 2018-09-27 ノバルティス アーゲー Ｍｄｍ２阻害剤およびその組み合わせ物
WO2017037586A1 (en) 2015-08-28 2017-03-09 Novartis Ag Combination therapy using pi3k inhbitor and mdm2 inhibitor
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
US10894830B2 (en) 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
HUE055509T2 (hu) * 2016-11-15 2021-12-28 Novartis Ag HDM2-p53-interakció-inhibitorok dózisa és adagolási rendje
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
PT3544982T (pt) * 2016-11-22 2022-01-06 Novartis Ag Processo químico para a preparação de derivados de imidazopirrolidinona e seus intermediários
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
WO2018161871A1 (zh) * 2017-03-06 2018-09-13 罗欣生物科技（上海）有限公司 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
WO2018185135A1 (en) 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3681503A1 (en) 2017-09-12 2020-07-22 Novartis AG Protein kinase c inhibitors for treatment of uveal melanoma
KR102613659B1 (ko) 2017-10-02 2023-12-15 노파르티스 아게 제약 제품의 제조 방법
US11406627B2 (en) * 2017-10-12 2022-08-09 Novartis Ag Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
WO2019099838A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
CA3087110A1 (en) 2017-12-29 2019-07-04 Gan & Lee Pharmaceuticals Compounds capable of being used as tumor inhibitor, preparation method thereof, and application thereof
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
JP7358372B2 (ja) * 2018-03-12 2023-10-10 羅欣薬業（上海）有限公司 イミダゾピロロン化合物及びその使用
CA3092307A1 (en) 2018-03-20 2019-09-26 Novartis Ag Pharmaceutical combinations
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN113194952A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
EP3898674A1 (en) 2018-12-21 2021-10-27 Novartis AG Use of il-1beta binding antibodies
CN113227137A (zh) 2018-12-21 2021-08-06 诺华股份有限公司 IL-1β抗体在骨髓增生异常综合征的治疗或预防中的用途
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3124939A1 (en) 2019-04-04 2020-10-08 Novartis Ag Siremadlin succinate
WO2021047466A1 (zh) * 2019-09-12 2021-03-18 罗欣药业(上海)有限公司 一种p53-MDM2抑制剂的晶型及其制备方法
EP4031139A1 (en) 2019-09-16 2022-07-27 Novartis AG Use of an mdm2 inhibitor for the treatment of myelofibrosis
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
AU2021333983A1 (en) 2020-08-27 2023-01-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using MDM2 antagonists
TW202218665A (zh) 2020-09-21 2022-05-16 德國阿爾伯特路德維希弗萊堡大學 用於治療或預防造血細胞移植後血液科贅瘤(neoplasm)復發之mdm2抑制劑
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
TW202329968A (zh) 2021-10-19 2023-08-01 瑞士商諾華公司 包含mdm2抑制劑、bcl2抑制劑和低甲基化劑的藥物組合及其用於治療血液惡性腫瘤之用途
WO2024097948A1 (en) * 2022-11-04 2024-05-10 Roivant Discovery, Inc. Degraders of mdm2 and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (ar) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
EP1110953B1 (en) 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0892789B2 (en) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Irreversible inhibitors of tyrosine kinases
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP4662635B2 (ja) 1998-11-20 2011-03-30 コーサン バイオサイエンシーズ， インコーポレイテッド エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MXPA03001169A (es) 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ES2301717T3 (es) * 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
WO2003095625A2 (en) 2002-05-13 2003-11-20 3-Dimensional Pharmaceuticals, Inc. Method for cytoprotection through mdm2 and hdm2 inhibition
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
JP4814228B2 (ja) 2004-05-18 2011-11-16 エフ．ホフマン−ラ ロシュ アーゲー 新規ｃｉｓ−イミダゾリン
DK1809622T3 (da) * 2004-09-22 2010-11-08 Janssen Pharmaceutica Nv Inhibitorer af interaktionen mellem MDM2 og P53
US20060069085A1 (en) 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160869A1 (en) 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
JP5222731B2 (ja) 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピロロ−ピラゾール誘導体
WO2007096334A1 (en) 2006-02-24 2007-08-30 Pfizer Italia Srl Pyrrolopyrrolones active as kinase inhibitors
WO2008034039A2 (en) 2006-09-15 2008-03-20 Nexuspharma Inc. Novel tetrahydro-isoquinolines
CN101679246A (zh) 2007-03-30 2010-03-24 盐野义制药株式会社 新型吡咯啉酮衍生物以及包含其的药物组合物
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2336109A4 (en) 2008-09-25 2012-05-02 Shionogi & Co NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
US20120208204A1 (en) 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
WO2013080141A1 (en) * 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
UY34591A (es) * 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物

Also Published As

Publication number Publication date
US20140011798A1 (en) 2014-01-09
HK1198761A1 (en) 2015-06-05
KR101694383B1 (ko) 2017-01-23
CN104203952A (zh) 2014-12-10
KR20140121851A (ko) 2014-10-16
BR112014018475A8 (pt) 2021-10-19
EP2807164B1 (en) 2017-04-05
JP2015509103A (ja) 2015-03-26
LT2807164T (lt) 2017-07-10
GEP20166438B (en) 2016-02-25
ES2743962T3 (es) 2020-02-21
TW201333012A (zh) 2013-08-16
TWI579284B (zh) 2017-04-21
CL2014001855A1 (es) 2014-12-05
ES2632430T3 (es) 2017-09-13
EP2807164A1 (en) 2014-12-03
CR20140354A (es) 2014-09-09
IL233739A (en) 2017-07-31
MX2014009089A (es) 2015-06-17
NI201400083A (es) 2014-12-22
CA2860951C (en) 2020-07-21
MX353315B (es) 2018-01-08
JP2017125037A (ja) 2017-07-20
EP3272754A1 (en) 2018-01-24
US20140343084A1 (en) 2014-11-20
AU2013213260A1 (en) 2014-08-14
AU2013213260B2 (en) 2016-02-18
CO7010838A2 (es) 2014-07-31
BR112014018475A2 (ar) 2017-06-20
ECSP14015553A (es) 2015-11-30
CU20140091A7 (es) 2014-12-26
DK2807164T3 (en) 2017-07-17
JP2016106095A (ja) 2016-06-16
CN104203952B (zh) 2016-10-19
WO2013111105A1 (en) 2013-08-01
GT201400164A (es) 2015-06-02
MY177242A (en) 2020-09-09
TN2014000319A1 (en) 2015-12-21
EP3272754B1 (en) 2019-05-29
EA201491423A1 (ru) 2014-11-28
MA35869B1 (fr) 2014-12-01
BR112014018475B1 (pt) 2021-11-09
RS56197B1 (sr) 2017-11-30
TW201713644A (en) 2017-04-16
PH12014501702B1 (en) 2014-10-13
CY1119058T1 (el) 2018-01-10
HK1245780B (zh) 2020-01-17
SI2807164T1 (sl) 2017-08-31
EA201790134A2 (ru) 2017-05-31
EA201790134A3 (ru) 2017-08-31
KR20160150292A (ko) 2016-12-29
JP5865519B2 (ja) 2016-02-17
EA027130B1 (ru) 2017-06-30
UY34591A (es) 2013-09-02
PT2807164T (pt) 2017-07-13
SG11201403935VA (en) 2014-10-30
AP2014007810A0 (en) 2014-07-31
PL2807164T3 (pl) 2017-09-29
DOP2014000170A (es) 2014-09-15
AR089807A1 (es) 2014-09-17
HRP20171005T1 (hr) 2017-09-22
UA115231C2 (uk) 2017-10-10
NZ627277A (en) 2015-12-24
EP3064502A1 (en) 2016-09-07
PE20141655A1 (es) 2014-11-14
US8815926B2 (en) 2014-08-26
CA2860951A1 (en) 2013-08-01
CU24336B1 (es) 2018-04-03
PH12014501702A1 (en) 2014-10-13

Similar Documents

Publication Publication Date Title
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
GB201209613D0 (en) New compounds
GB201118656D0 (en) New compounds
EA201500536A1 (ru) Триазолопиразин
MX366899B (es) Nuevos compuestos.
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX349004B (es) Nuevos compuestos.
PH12015501609A1 (en) Phenicol antibacterials
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
GEP201706621B (en) Benzamides
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA033160B1 (ru) Соединения для лечения заболеваний, связанных с ишемией-реперфузией
IN2014DN10683A (ar)
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists